Edaravone Intravenous (Radicava, generic)

Intravenous edaravone (Radicava, generic) is covered for ALS but excluded for patients who do not meet El Escorial/revised Airlie House "definite" or "probable" criteria, who have any ALSFRS‑R item <2, who require invasive (mechanical) ventilation, or who have not received/are not receiving riluzole. Key requirements: 6‑month approvals; initial dosing 60 mg IV daily ×14 days then 14‑day drug‑free, subsequent cycles 60 mg IV daily 10 of 14 days then 14‑day drug‑free; prescribing by or in consultation with a neurologist/ALS specialist; documentation of diagnosis, ALSFRS‑R scores ≥2 on all items, adequate respiratory function, riluzole use, infusion/dosing records, and documented continued benefit for reauthorization.

"Edaravone intravenous is indicated for the treatment of amyotrophic lateral sclerosis (ALS)."

Sign up to see full coverage criteria, indications, and limitations.